Recent Updates
Recently added Catalysts
EOLS Positive Sentiment

Evolus to Report Third Quarter Financial Results on November 4, 2026

Wednesday, October 21, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Evolus, Inc. announced it will report its third quarter financial results on November 4, 2026. The results will be shared after the U.S. markets close, followed by a conference call at 4:30 p.m. ET. This call will include a question-and-answer session for further engagement.

Market Sentiment Analysis

POSITIVE FACTORS

  • Evolus is set to report its Q3 2026 financial results.
  • Management will host a conference call for discussion.
  • The event includes a Q&A session for stakeholders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~36 mo
Minimal dilution risk
Lead asset
Botulinum toxin, Type A
Phase 3 · Glabellar Frown Lines

Full Press Release Details

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026, after the U.S. financial markets close.Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management’s remarks.To p

Frequently Asked Questions

When will Evolus report its Q3 2026 results?

Evolus will report its Q3 2026 financial results on November 4, 2026.

What time is the Evolus conference call?

The conference call will be held at 4:30 p.m. ET on November 4, 2026.

Will there be a Q&A session after the results?

Yes, a question-and-answer session will follow the management's remarks.

What is the focus of Evolus as a company?

Evolus focuses on building an aesthetic portfolio of consumer brands.

ShareAdd on Google
Tags: EOLS Evolus financial results Q3 2026 conference call
Last updated: Oct 21, 2026

Biotech snapshot

Cash runway
$45M liquidity · $1M/mo burn
~36 mo
Minimal dilution risk
Lead asset
Botulinum toxin, Type APhase 3
Glabellar Frown Lines →